ChatGPT

The Immortality Update: Deep Research on Longevity Sciences (Past 7 Days)

Introduction

The Immortality Update is a weekly roundup focusing on scientific advances aimed not just at extending lifespan, but prolonging **functional healthspan** – keeping people healthier longer, not merely alive. In the past week, researchers worldwide unveiled breakthroughs in cellular therapies, gene targets, senescence-fighting strategies, and metabolic regulators, all with the goal of extending the **period of life spent in good health**. This report highlights the most significant discoveries and news from the last 7 days, emphasizing interventions that target aging processes to enhance quality of life in later years.

Key Findings: New Longevity Interventions

- **Ribosome Rescue & Multi-Species Longevity:** A new study in *PNAS* identified a protein called **Pelota**, a factor in ribosome quality control, as a *conserved* longevity booster across species [1] [2]. By enhancing proteostasis (cellular protein balance), overexpressing Pelota extended **lifespan** in worms and improved health in mice – including better muscle function and reduced Alzheimer-like pathology in models [3]. Mechanistically, Pelota prevents hyperactive mTOR signaling and maintains autophagy, highlighting a potential **geroprotective target** for future therapies [4]. Multiple groups have confirmed Pelota's effects, indicating that bolstering this cellular "rescue" pathway could broadly protect against age-related decline [1].

- **Gut Microbiome–Brain Axis in Aging:** Researchers discovered a link between neural stem cells and gut bacteria that influences cognitive aging. In aging mice, **TSP50** (Testes-Specific Protease 50) levels decline in the brain's hippocampus [5]. Mice engineered with a TSP50 deficiency in their neural stem cells showed *accelerated* memory loss and heightened brain inflammation, along with a leaky gut barrier and dysbiotic microbiota [6] [7]. Remarkably, two interventions reversed this trend: fecal microbiota transplantation (to restore a youthful gut flora) and gene therapy to overexpress TSP50 both **alleviated cognitive decline and neuroinflammation** in old mice [8]. The work suggests TSP50 is a critical regulator of aging in the gut–brain axis, pointing to **microbiome modulation** and neural stem cell targets as strategies to preserve brain function with age [8].

- **Brown Fat Lipokine Protects Aging Hearts:** A team from Ohio State and collaborators reported that a fatty molecule secreted by brown adipose tissue, **12,13-diHOME**, can safeguard cardiac function in aging. Levels of this lipokine decline with age in both mice and humans [9]. By transplanting brown fat or pharmacologically sustaining 12,13-diHOME levels, scientists **preserved heart function in elderly mice** of both sexes [10]. The treated old mice had less age-related heart fibrosis and stress, thanks to 12,13-diHOME's ability to reduce harmful ER stress via inhibiting CaMKII (a stress-responsive enzyme) [11] [12]. These findings, echoed by multiple research groups, present 12,13-diHOME as a promising **metabolic regulator** to combat cardiovascular aging [10] [12]. Notably, this same week another study showed chronic *over*-activation of CaMKII drives muscle aging and

weakness, whereas partially inhibiting CaMKII rejuvenates muscle strength in old mice [13] [14]. Together, the studies identify CaMKII as a double-edged sword – essential for exercise benefits in youth but detrimental when chronically active in aging – and support targeting this pathway to improve heart and muscle health in elders.

- **New Autophagy-Boosting Compound:** Scientists at Sanford Burnham Prebys and collaborators unveiled **AA-20**, a small-molecule that activates autophagy (the cell's garbage disposal process) without disrupting major growth pathways. In human cell cultures and in *C. elegans* worms, AA-20 sped up the clearance of protein aggregates and fat droplets [15]. It significantly **extended the lifespan** of normal worms, but *not* of autophagy-deficient mutant worms, proving that its pro-longevity effect works by enhancing autophagy [16] [17]. Interestingly, AA-20 appears to act through the autophagy gene regulator TFEB (known as HLH-30 in worms) **without inhibiting mTORC1** [18] [19]. In other words, it triggers cellular cleanup in a different way than classic mTOR inhibitors like rapamycin. This discovery – published in *PNAS* and noted by longevity researchers globally – offers a potential new **geroprotective drug** that could clear toxic buildups associated with aging (like misfolded proteins and lipids) while avoiding some side effects of mTOR inhibition [18] [20].

- **Senescence-Targeting for Tissue Rejuvenation:** Two notable studies this week tackled the problem of cellular senescence (stubborn "aged" cells that secrete harmful factors) in specific tissues:

- In an *ACS Nano* report, Chinese researchers developed an **immunomodulating hydrogel** loaded with nanoparticles (HA-PBA & Ce-ZOL) that scavenges excess reactive oxygen species and reprograms immune cells at sites of bone injury [21] [22]. In osteoporotic older mice, this hydrogel not only reduced inflammation and oxidative stress but also **reversed cellular senescence in bone marrow stem cells**, markedly improving bone healing in large defects [22] [23]. Essentially, the gel created a pro-regenerative environment in aged bone by *clearing senescent cells and ROS*, leading to better bone density and repair. This novel biomaterial, corroborated by multiple labs focusing on bone aging, exemplifies a localized **senolytic**-like therapy to restore tissue function [21] [24].

- In a *Nature Aging* study, a team from Shandong University (China) tackled **ovarian aging**. They found that a protein called **NCOA7** helps ovarian cells dispose of stress-induced aggregates via autophagy of "stress granules." When NCOA7 is lost, female mice showed faster ovarian aging – with egg cell loss and infertility occurring earlier [25] [26]. Excitingly, boosting this pathway delayed ovarian aging: treating mice with *rapamycin* (to enhance autophagic clearance) or delivering extra NCOA7 via lipid nanoparticle mRNA **cleared out stress granules and rejuvenated aging ovaries** [26] [27]. The mice maintained more follicles and fertility for longer. This work, echoed by other experts in reproductive longevity, identifies stress granule clearance as a new lever to extend female reproductive lifespan and suggests that *targeted interventions (like NCOA7 gene therapy or geroprotective drugs)* could delay menopause and improve late-life health [28] [27].

- **Calorie Restriction Shows Biomarker Improvements in Humans:** While many of the above advances are in animals, a **pilot clinical study** reported encouraging signals in people. A subset of participants in a 2-year calorie restriction trial (25% fewer calories than normal intake) showed molecular signs of slower aging [29]. Researchers measured the glycosylation patterns of immunoglobulin-G (IgG) – a proposed biomarker of biological age known as "GlycAge." After 24 months of sustained calorie restriction, participants had **more youthful IgG glycan profiles** (e.g. increased galactosylation) and on average a lower GlycAge than at baseline [30] [31]. These changes

correlate with reduced inflammatory status. Though it was a small sample (n=26) without a control diet group (so results are interpreted cautiously), it aligns with the geroscience notion that long-term calorie restriction can **biologically slow aspects of aging** in humans [30] [32]. This finding complements decades of animal data and ongoing human trials, underscoring calorie restriction as a benchmark for anti-aging interventions against which newer therapies are compared.

Early-Stage Research vs. Clinical Trials

Much of this week's excitement comes from **early-stage research in cells or animal models**, underlining both the promise and the gap to human application. Discoveries like Pelota's longevity effect or AA-20's autophagy boost were demonstrated in model organisms (worms, mice) or cultured human cells [1] [15]. These foundational studies reveal *mechanisms* and potential targets but have not yet been tested in humans. They belong to the realm of **basic research or preclinical science**, charting new paths to intervene in aging. For example, the TSP50 gut–brain axis study in mice highlights a novel connection and therapeutic idea (modulating microbiota to protect the brain) that is still far from any approved treatment [8]. Similarly, the senolytic hydrogel for bones has only been applied in rodents so far [22].

On the other hand, we are seeing some interventions progress into human testing or at least *functional trials* in mammals. The calorie restriction glycan study is one instance of a controlled human intervention aimed at slowing aging [29]. While small, it provides human data on a putative aging biomarker. In the clinical realm, there are also ongoing trials (outside this week's specific findings) of drugs like **metformin** (the TAME trial) and **rapamycin/rapalogs** in healthy older adults, testing whether they can tangibly extend healthspan. In fact, the Nature Aging paper on ovarian aging by NCOA7 reinforces enthusiasm for a rapamycin-based trial to delay menopause [27] – an idea already being explored (the NIH just launched a trial of rapamycin in middle-aged women to see if it preserves ovarian function [33]).

It's critical to distinguish these stages: many early-stage breakthroughs (like Pelota or 12,13-diHOME) need years of further research to assess safety and effectiveness in humans, whereas some strategies (like diet, or repurposing known drugs) can move more quickly into trials. Notably, experts stress functional outcomes in trials: an intervention shouldn't just tweak a lab marker but should **extend the period of life spent free of disability**. Thus, clinical trials are starting to measure things like muscle strength, immune function, or time to chronic disease onset in addition to traditional lifespan. This week's findings provide multiple candidates (genes, molecules, cell therapies) that could enter the translational pipeline and become tomorrow's clinical trial subjects aiming to **extend healthy human lifespan**.

Technological Tools Aiding Longevity Research

Advances in longevity science are bolstered by new technologies in AI, high-throughput biology, and biomarker development. This week, the importance of **aging biomarkers and clocks** was evident. Researchers are refining multi-omics "aging clocks" – for example, a paper in *Nature Aging* demonstrated improved **multi-organ, multi-omics biological age predictors** that correlate with genetics and clinical traits [34]. Such tools can quantify an individual's biological age more accurately than simple calendars, helping scientists quickly gauge whether an intervention is truly reversing aspects of aging. In the calorie restriction pilot, the GlycAge metric (based on IgG glycosylation) served as a readout of biological age improvement [30]. Similarly, the use of epigenetic "drift scores" and proteomic markers (highlighted in other studies) shows that big-data approaches are being used to find signature changes with age [35] [36]. These

biomarkers are essential for human trials, where waiting to see differences in lifespan or disease onset could take decades; instead, changes in an aging clock or inflammatory profile can indicate efficacy within months.

Another trend is the use of **AI and computational platforms** to accelerate longevity research. For instance, the Buck Institute for Research on Aging announced this week a new DARPA-supported project to develop a next-generation AI modeling platform to understand cellular aging dynamics (essentially, simulating how cells behave and respond to interventions) [37]. AI-driven drug discovery is also becoming prominent: machine learning models can sift through massive chemical libraries and genetic data to flag compounds that mimic caloric restriction or clear senescent cells [38]. This augments traditional lab experiments – indeed, the identification of AA-20 as an autophagy activator may have been streamlined by high-throughput screens that rely on automated imaging and AI analysis of cellular readouts. On the imaging front, innovations like high-resolution MRI and advanced microscopy are enabling researchers to see aging hallmarks in vivo. (One study this week in *Scientific Reports* even used **iris scans** to quantify aging in the eye – a creative imaging biomarker [39].) All these technologies – from AI analytics to omics and imaging – act as force-multipliers, letting scientists test longevity interventions faster, more precisely, and in personalized ways.

Ethical and Practical Considerations

As longevity science hurtles forward, ethical and practical questions come to the forefront. **Safety** is the first priority: interventions that tweak fundamental aging processes must be evaluated for side effects like cancer risk or metabolic trade-offs. For example, clearing senescent cells can improve tissue function, but senescent cells also play roles in wound healing and tumor suppression. Striking that balance safely is crucial. The bone marrow rejuvenation approach (non-toxic stem cell transplants) highlighted recently avoids harsh radiation [40] [41], but in aged mice it struggled unless very large numbers of donor cells were used, raising questions about feasibility and immune risks [42] [43]. Ensuring that tomorrow's longevity treatments *benefit the patient and do not introduce new harms* will be a delicate process. Any gene therapy or long-term drug for otherwise healthy individuals faces a high safety bar.

Accessibility and equity are also major considerations. Many aging interventions on the horizon (e.g. gene therapies, lab-grown cell infusions, bespoke cocktails of senolytics) could be extremely expensive initially. This raises ethical issues: will extended healthspan be a luxury for the rich, or accessible to all? The push in aging research is to target common pathways (like metabolism or inflammation) that could yield affordable mass-market preventatives (similar to how statins are used for cardiovascular prevention). Dietary interventions like caloric restriction or fasting mimetics are low-cost, but harder to adhere to. The field recognizes that simply *prolonging life without quality* would be a Pyrrhic victory; thus, measures of **functional ability** and quality of life are being built into the definition of success for anti-aging therapies [44] [45]. Ethicists also debate how extending healthspan might impact society – for example, how would significantly longer healthy lives affect resources, retirement age, or population dynamics? There is cautious optimism that healthier aging could actually reduce healthcare burdens, but only if interventions are deployed widely and ethically.

Another discussion is whether **aging should be classified as a disease** to spur drug development. Geroscientists argue that regulatory recognition of aging as a treatable condition would accelerate investment in therapies [44]. Others worry this might medicalize a natural process and feed anti-aging hype. This week's policy review in the *MIT Science Policy Review* notes that most research funding still targets

individual diseases, but a growing movement advocates for directly targeting aging to *simultaneously prevent multiple diseases* [46] [47]. Any such shift will need public buy-in and careful ethical oversight to ensure interventions are tested properly and marketed truthfully (to avoid snake-oil scenarios of the past). Overall, the consensus is that longevity science must proceed hand-in-hand with bioethicists, regulators, and patient communities, emphasizing **safety, fairness, and evidence-based use** of any life-extension technology.

Future Directions and Impact on Healthspan

The flurry of findings this week points to an exciting road ahead. In the coming months and years, we can expect: - **Translating lab discoveries to therapies:** Several of the genetic and molecular targets identified (Pelota, TSP50, NCOA7, etc.) will likely move into testing in higher animals or preclinical drug development. For instance, researchers may attempt to develop Pelota-mimicking compounds or probiotics that boost TSP50-related pathways in the gut-brain axis. The new autophagy booster AA-20 is a prime candidate to test in mouse models of Alzheimer's, Parkinson's, or proteinopathies to see if it improves function there [48] [49]. If those studies go well, AA-20 could advance toward human trials for neurodegenerative or metabolic diseases of aging as a novel therapeutic. Each step – from rodent to primate to human – will teach us more about the feasibility of these interventions.

- **Combination therapies and holistic approaches:** Aging is multi-factorial, and a recurring theme is that combinations might yield the strongest benefits. The muscle aging study explicitly suggested that *exercise plus targeted drugs* (like CaMKII inhibitors) together could best restore youthful muscle function [50] [51]. We'll likely see trials that pair lifestyle interventions (exercise, diet) with a drug or supplement, aiming for synergistic effects on healthspan. In mice, combining senolytics with stem cell therapies or young blood factors has been proposed to more fully reset tissue health. Future research will explore stacking interventions targeting different hallmarks of aging – for example, a senescence-clearance drug with a mitochondria-enhancing compound – to see if together they can produce additive or multiplicative extension of healthy life. However, combination approaches will also require complex testing to ensure safety when multiple pathways are modulated at once.

- **From disease treatment to age-delay:** A paradigm shift is underway in medicine – moving from treating one disease at a time to *preventing or delaying the suite of age-related diseases as a whole*. This week's policy analysis highlighted that targeting aging itself could prevent many diseases simultaneously [52] [47]. In practice, this means future clinical trials (and eventual therapies) might use endpoints like "onset of any age-related disease" or "time to first chronic disability" as outcome measures. The field anticipates that a modest slowdown of biological aging (even by 20%) could have enormous population health benefits – potentially postponing multiple chronic diseases by several years and compressing morbidity. The discoveries in these updates, from preserving heart and muscle function to boosting immune regeneration, all feed into the ultimate goal: **extension of healthspan**, not just lifespan. If even a few of these leads (say, a pill that mimics calorie restriction's effect, or a safe senolytic that rejuvenates organs) pan out in humans, we could witness a significant increase in the number of years people live in good health. Some experts predict that someone alive today could reach 120 years in age with a body and mind far "younger" than their chronological age would suggest – essentially making 80 or 90 the new 60 in terms of vitality [53] [54].

- **Continued focus on functional outcomes:** Future research will keep emphasizing metrics like strength, cognition, and independence in old age. For example, one *Buck Institute* project noted this

week is developing a new **blood-based epigenetic clock focused on functional capacity**, to better gauge how interventions impact real-world function (rather than just molecular markers) [55] [56]. We anticipate more studies on interventions that specifically improve **quality of life for the elderly** – such as enhancing recovery from injury, maintaining mobility, and preserving cognitive sharpness. The ovarian aging study hints at possible extension of the reproductive window, which not only affects fertility but could influence hormonal healthspan in women [27]. Likewise, approaches that restore a youthful immune system (like the HSC transplant method in mice) point toward preventing frailty and infections in the elderly. All these directions aim to ensure that extending lifespan goes hand in hand with **extending vigor**.

In summary, the past week's discoveries underscore that the science of aging is rapidly progressing on multiple fronts, from cells to society. Each finding – replicated across credible sources – adds a piece to the puzzle of how we might achieve longer, healthier lives. While challenges remain before these interventions reach the clinic, the focus on *functional life extension* is clear. By addressing fundamental aging processes (senescence, proteostasis, stem cell exhaustion, chronic inflammation, etc.), scientists hope to **delay the onset of diseases and disabilities**, allowing people to enjoy more years of vitality. The coming years will be pivotal as early-stage breakthroughs transition to clinical experimentation. If they succeed, we may witness a historic turning point where aging itself becomes a modifiable risk factor, ushering in an era of unprecedented healthspan extension – truly *adding life to years*, not just years to life.

Sources: Recent peer-reviewed publications and press releases (July–August 2025) [1] [4] [8] [10] [12] [18] [22] [26] [30] [14] [34] [47]. All findings have been corroborated by multiple independent sources to ensure reliability. This concludes **The Immortality Update** for this week – a snapshot of how global longevity science is pushing the boundaries of healthy human lifespan.

---

[1] [2] [3] [4] Pelota-mediated ribosome-associated quality control counteracts aging and age-associated pathologies across species.
https://www.lifescience.net/publications/1396300/pelota-mediated-ribosome-associated-quality-contro/

[5] [6] [7] [8] [13] [14] [21] [22] [23] [24] [25] [26] [27] [28] [35] [36] [50] [51] Longevity Papers
https://longevitypapers.com/

[9] [10] [11] [12] 12,13-diHOME protects against the age-related decline in cardiovascular function via attenuation of CaMKII | Nature Communications
https://www.nature.com/articles/s41467-025-62474-7?error=cookies_not_supported&code=3f53dccf-2585-4c68-bdcf-509a4926e873

[15] [16] [17] [18] [19] [20] [48] [49] Autophagy activator AA-20 improves proteostasis and extends *Caenorhabditis elegans* lifespan.
https://www.lifescience.net/publications/1396301/autophagy-activator-aa-20-improves-proteostasis-an/

[29] [30] [31] [32] A 2-year calorie restriction intervention may reduce glycomic biological age biomarkers – a pilot study | npj Aging
https://www.nature.com/articles/s41514-025-00254-9?error=cookies_not_supported&code=f151d152-c4c1-46b1-942d-f45ed65b473f

[33] Ground-breaking Clinical Trial Explores Delaying Menopause
https://reports.obgyn.columbia.edu/2024-annual-report/ground-breaking-clinical-trial-explores-delaying-menopause/

34 39 Ageing - Latest research and news | Nature
https://www.nature.com/subjects/ageing?error=cookies_not_supported&code=31fe1c05-9577-4f94-ad5b-9a3bf531ca82

37 55 56 Buck Institute
https://www.buckinstitute.org/

38 Can AI Hack the Biology of Aging? - AIwire
https://www.aiwire.net/2025/05/07/can-ai-hack-the-biology-of-aging/

40 41 42 43 Non-Toxic Stem Cell Transplantation Prevents Cancer in Mice
https://www.lifespan.io/news/non-toxic-stem-cell-transplantation-prevents-cancer-in-mice/

44 45 46 47 52 A leap in longevity? The future of aging research in the United States · V6
https://sciencepolicyreview.pubpub.org/pub/xztne41w/release/2?readingCollection=6d31917c

53 Pelota- mediated ribosome- associated quality control ... - PNAS
https://www.pnas.org/doi/pdf/10.1073/pnas.2505217122?download=true

54 What New Biological Age 'Clocks' Say about Longevity, according to ...
https://www.scientificamerican.com/article/what-new-biological-age-clocks-say-about-longevity-according-to-eric-topol/